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century. Both tramadol (synthetic opioid) and dexmedetomidine (a2-agonist) can act locally.
Aim of the work: To compare effects of adding tramadol versus dexmedetomidine to lidocaine dur-
ing IVRA.
Patients and methods: Sixty patients were randomly assigned into: Group C (n= 20), Group T
(n= 20), and Group D (n= 20). All patients received 3 mg/kg 0.5% lidocaine [+100 mg tramadol
in Group T, or 1 lg/kg dexmedetomidine in Group D]. Times of onset and offset of sensory and
motor blocks, and time to tourniquet pain were recorded. Postoperative VAS score, time to ﬁrst
dose, and total amounts of supplementary analgesia (Paracetamol) were recorded. Sedation was
evaluated using Ramsay sedation scale (RSS).
Results: Signiﬁcantly shorter onset times and longer recovery times of sensory and motor block
were recorded in Groups T and D compared to Group C (P< 0.05); while, with no signiﬁcant
differences between Groups T and D. Delayed onset of tourniquet pain occurred in Groups T
and D compared to Group C (P< 0.05) with no signiﬁcant differences between Groups T and
D. Fourteen patients required fentanyl to control tourniquet pain in Group C compared to (5
and 4) in Groups T and D respectively. Signiﬁcantly lower Postoperative VAS score, longer time
to ﬁrst dose and lower consumption of Paracetamol were recorded in Groups T and D than Group
C; with no signiﬁcant differences between Groups T and D. Complications were skin rash in 30% of
patients in Group T, bradycardia and sedation in 35% and 65% of patients in Group D respec-
tively.29364.
(S.H. Waly).
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38 Y.M. Nasr, S.H. WalyConclusion: Addition of either tramadol or dexmedetomidine enhances lidocaine during IVRA
with higher incidence of skin rash with tramadol and postoperative bradycardia and sedation with
dexmedetomidine.
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Intravenous regional anesthesia (IVRA) is a technique that
should be honored for playing a respected role in anesthesia
for more than one hundred years. It was ﬁrst performed by a
German scientist named August Bier in 1908 (thereby, the
technique was named after him as Bier’s block) [1]. It has many
advantages being a simple and easy technique, reliable with
high success rate, and cost-effective [2]. Many researches have
been aiming to overlap the disadvantages of this type of block
including tourniquet pain and insufﬁcient postoperative pain
relief by using adjuvant drugs to potentiate local anesthetics
such as tramadol [3], a2-agonists [4], neostigmine [5], or non-
steroidal anti-inﬂammatory drugs (NSAIDs) [6].
Tramadol is a centrally acting synthetic opioid that has
been widely used. It has weak agonist actions at the l-opioid
receptor, releases serotonin, and inhibits the reuptake of nor-
epinephrine [7,8].
Opioids possess local anesthetic properties in vitro [9]
Despite that the use of morphine [10] and fentanyl [11] showed
a limited role, yet, meperidine enhanced lidocaine in IVRA [12]
and proved efﬁcacy when even used alone [13].
Dexmedetomidine, is a2-adrenoceptor agonist that has been
the subject of many anesthetic researches owing to its sedative
and analgesic effects [14]. It has a ratio of selectivity towards
a2/a1 receptors of 1620:1 compared to 220:1 for clonidine.
Therefore, is considered as a full agonist of the a2 receptor
(with more potent neurological and less cardiovascular effects)
[15].
In the current study we aimed to compare the effects of
tramadol versus dexmedetomidine when added to lidocaine
during intravenous regional anesthesia.
2. Patients and methods
After approval of our committee and obtaining written con-
sent from each patient;
Sixty patients of both sexes with American Society of Anes-
thesiologists (ASA) physical status I or II, aged between 20
and 50 years, who were scheduled for short procedure surgery
of the hand or the forearm (ganglion excision, carpal tunnel
syndrome, fractured radius, fractured ﬁnger, and hardware
removal of forearm) in Zagazig University Surgical Hospital
were included in this study. Exclusion criteria included: history
of drug allergy, cardiac disease, hypertensive patients treated
with a-methyldopa or clonidine, patients who were given any
analgesia within the last 24 h, liver disease, kidney disease, or
sickle cell anemia.
Patients were randomly assigned into three groups: Group
C-patients received 3 mg/kg 0.5% lidocaine diluted with 0.9%
normal saline to a total volume of 40 ml (n= 20), Group
T-patients received 3 mg/kg 0.5% lidocaine + 100 mg trama-
dol (Tramal 100 mg/2 ml; MINAPHARM under license of
GRUNENTHAL, Germany) diluted with 0.9% normal salineto a total volume of 40 ml (n= 20) and Group D-patients
received 3 mg/kg 0.5% lidocaine + 1 lg/kg dexmedetomidine
(Precedex 200 lg/2 ml; Abbott, North Chicago, IL) diluted
with 0.9% normal saline to a total volume of 40 ml (n= 20).
Before starting the block with IVRA, two cannulae
(20 gauge) were applied; one in dorsal vein of the hand near
the site of surgery through which anesthetic drugs are to be
given, and the other in opposite hand for intra-operative ﬂuid
transfusion.
Esmarch bandage was used for exsanguination of the oper-
ative arm, and a pneumatic tourniquet was placed around the
upper arm. The proximal cuff was inﬂated to 250 mm Hg. The
proper performance of the tourniquet was assured by inspec-
tion of the limb pallor, absence of radial pulse, and loss of
pulse oximetry tracing of the ipsilateral index ﬁnger. After
the bandage was removed, the prepared anesthetic solution
was injected over 1 min in a double-blinded, randomized fash-
ion by using a closed envelope system.
The sensory block was assessed every 30 s starting 2 min
after injection until complete sensory block was established
in the dermatomal sensory distribution of the ulnar, median,
and radial nerves by a pinprick test using a 22-gauge short-
beveled needle. Sensory loss was evaluated by testing dermato-
mal distribution of each nerve based on the hypothesis that
‘‘different nerve ﬁbers have a varying susceptibility to block-
ade’’ [16] as follows: (1) ventral aspect of the forearm and ﬁrst
webspace (radial nerve); (2) thenar eminence and index ﬁnger
(median nerve); (3) hypothenar eminence and little ﬁnger
(ulnar nerve). Motor function was evaluated by asking the
patient to ﬂex and extend his wrist and ﬁngers.
When sensory and motor block was ensured, the distal cuff
was then inﬂated to 250 mm Hg followed by release of the
proximal tourniquet. Surgical intervention was then allowed.
The visual analog scale (VAS) which was used to evaluate
tourniquet pain (0 = no pain and 10 = worst pain imagin-
able) was recorded at the times of 5, 10, 15, 25, 35 and
45 min after tourniquet application. 1 lg/kg fentanyl was given
for relieving tourniquet pain when VAS > 3. Time to com-
plain of tourniquet pain was recorded for each patient (starting
point: just after tourniquet inﬂation).
The tourniquet was not deﬂated before 40 min of local
anesthetic injection and was not inﬂated more than 90 min.
At the end of surgery, the tourniquet deﬂation was
performed by repeated inﬂation-deﬂation technique (the tour-
niquet was deﬂated three times for 10 s period followed by
1 min of reinﬂation). Time till regaining of sensation and
motor power was recorded starting just after tourniquet
release.
For all patients, mean arterial blood pressure (MAP),
peripheral oxygen saturation (SpO2), and heart rate (HR) were
monitored. Hypotension was considered if 30% decrease
below baseline MAP occurred and was planned to be treated
with IV ephedrine (6 mg bolus). Bradycardia was considered
if P25% decrease from baseline value occurred and was
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arterial oxygen saturation <91% was treated with O2 via a
transparent face mask.
Postoperative analgesia was evaluated using VAS every
30 min after tourniquet deﬂation for 2 h in postanesthesia care
unit (PACU) with the highest value of VAS for each patient
considered as postoperative VAS score. During the ﬁrst 24 h
after surgery, the time to ﬁrst dose of supplementary analgesia
was recorded to each patient starting just after tourniquet
deﬂation [patients received IV Paracetamol (Perfalgan) 1 g
when VAS was >3], and total amounts of Paracetamol admin-
istered to each group were recorded.
Patients’ degree of sedation was evaluated using Ramsay
sedation scale (RSS) [17] at 5, 10, 15, 25, 35 and 45 min after
tourniquet deﬂation with the highest value of RSS for each
patient considered as postoperative RSS score. RSS has six
different levels:
1. Patient is anxious and/or agitated.
2. Patient is cooperative, oriented and tranquil.
3. Patient responds to commands only.
4. Patient exhibits brisk response to light glabellar tap or loud
auditory stimulus.
5. Patient exhibits a sluggish response to light glabellar tap or
loud auditory stimulus.
6. Patient exhibits no response.
2.1. Statistical analysis
It is clinical trial study, thus, sample size was calculated
(n= 60) by using pilot study to determine patients scheduled
for IVRA in one month then the whole patients (whole popu-
lation) for one year was calculated. Systematic random sample
technique was used for allocation of the three study groups.
Power of the study was 80%, conﬁdence interval was 95%,
level of signiﬁcance was determined at 5% (P< 0.05), and
expected non compliance (non-response rate) 20% was also
considered.
Data were checked, entered and analyzed using SPSS
version 11. Data were expressed as mean ± standard deviation
(SD) for parametric results. Qualitative data were expressed
as number. ANOVA, paired t-test, chi-square (v2) or
Krunskal–Wallis test were used when appropriate. P< 0.05
was considered signiﬁcant.3. Results
There were no signiﬁcant differences among groups for demog-
raghic data and total tourniquet time (Table 1).Table 1 Demographic data, and time of tourniquet pain.
Group C (n= 20)
Age (years) 36.0 ± 14.8
Gender (M/F) 10/10
Weight (kg) 75.2 ± 5.9
Surgical duration (min) 46.8 ± 16.9
Time of tourniquet application (min) 60.2 ± 14.5
Data were expressed as mean (±SD) as number.Sensory as well as motor block onset times (block perfor-
mance) were signiﬁcantly shorter in Groups T and D com-
pared to Group C (P< 0.05), with no signiﬁcant differences
between tramadol and dexmedetomidine groups. Sensory
and motor block recovery times were signiﬁcantly longer in
Groups T and D when compared to Group C (P < 0.05).
But no signiﬁcant differences between tramadol and dexmede-
tomidine groups [suggesting the equipotent adjuvant effect of
tramadol and dexmedetomidine when added to the lidocaine]
(Table 2).
Tourniquet pain onset time was signiﬁcantly longer in
Groups T and D than in Group C (P< 0.05) with no signiﬁ-
cant differences between tramadol and dexmedetomidine
groups. The numbers of patients who required fentanyl were
14 in Group C, 5 in Group T, and 4 in Group D with signiﬁ-
cantly higher number in Group C compared to Groups T and
D (Table 2).
Postoperative VAS score in Groups T and D compared to
Group C were signiﬁcantly lower (P< 0.001), while it was
comparable between both groups (T and D). Time to ﬁrst dose
of supplementary analgesia (Paracetamol) was signiﬁcantly
longer in Groups T and D compared to Group C, with no sig-
niﬁcant differences between tramadol and dexmedetomidine
groups. The postoperative analgesic consumption in the ﬁrst
24 h was signiﬁcantly lower in Group T and Group D than
Group C (P < 0.001), with no signiﬁcant differences between
tramadol and dexmedetomidine groups (Table 2).
As shown in Table 3, six of the patients (30%) in Group T
developed skin rash without itching within the ﬁrst 5 min after
injection of tramadol–lidocaine solution, below the tourniquet
level and it subsided spontaneously by the end of surgery [com-
pared to no patients (0%) in Groups D and C]. Seven patients
(35%) developed bradycardia just after tourniquet deﬂation in
Group D compared to no patients (0%) in Groups T and C.
This decrease in heart rate was accompanied by insigniﬁcant
decrease in blood pressure and all of them responded to
1 mg IV atropine (although patients in Group D recorded
lower levels of blood pressure after tourniquet deﬂation, the
results were statistically insigniﬁcant when compared to those
recorded in Groups C and T). Ramsay sedation score was
signiﬁcantly higher (RSS = 2) in 13 patients (65%) in Group
D compared to Groups C and T during the ﬁrst 30 min after
release of tourniquet. None of the patients in any group
developed hypotension or hypoxemia during surgery or during
the ﬁrst 24 h postoperatively.
4. Discussion
The current study revealed that addition of either tramadol or
dexmedetomidine to lidocaine for IVRA was accompanied by
more rapid onset and delayed offset of sensory and motorGroup T (n= 20) Group D (n= 20)
35.7 ± 14.2 38.2 ± 11.7
11/9 11/9
74.6 ± 3.6 74.7 ± 7.8
44.0 ± 22.1 42.9 ± 25.1
57.3 ± 13.3 57.1 ± 14.0
Table 3 Incidence of complications between the three groups.
Group C (n= 20) Group T (n= 20) Group D (n= 20)
Skin rash within the ﬁrst 5 min 0 6 (30%)* 0
Bradycardia just after tourniquet deﬂation 0 0 7 (35%)*
Ramsay sedation score of [RSS = 2] during the ﬁrst 30 min 0 0 13 (65%)*
Data were expressed as number or percent.
* P< 0.05 considered signiﬁcant.
Table 2 Performance of intra-operative anesthesia and postoperative analgesia of different agents used in the study.
Group C (n= 20) Group T (n= 20) Group D (n= 20)
Sensory block
Onset time (min) 3.6 ± 1.8 2.2 ± 1.2* 2.0 ± 1.7*
Recovery time (min) 3.2 ± 2.0 8.1 ± 1.1 9.6 ± 0.7
Motor block
Onset time (min) 7.2 ± 1.3 4.5 ± 2.1* 3.9 ± 2.3*
Recovery time (min) 3.7 ± 3.1 9.4 ± 2.1 10.2 ± 1.3
First time to complain of tourniquet pain (min) 25.1 ± 2.3 33.9 ± 8.9 34.2 ± 5.9
Number of patients who needed fentanyl (VAS > 3) 14 5* 4*
Postoperative VAS scores 3.9 ± 2.6 2.2 ± 1.7* 1.8 ± 1.3*
Time to ﬁrst dose of postoperative supplementary analgesia (Paracetamol) (min) 119.1 ± 12.3 242.4 ± 9.6 269.9 ± 9.1
Total dose of consumption of Paracetamol (g) in the ﬁrst 24 h 2.44 ± 0.6 1.20 ± 0.1* 1.1 ± 0.3*
Data were expressed as mean (±SD) number.
* Signiﬁcantly less compared to Group C (P< 0.05).
 Signiﬁcantly more compared to Group C (P< 0.05).
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onset of postoperative pain, and less postoperative consump-
tion of supplementary analgesia. Tramadol was accompanied
with higher incidence of skin rash that subsided spontaneously,
while, dexmedetomidine was accompanied by higher incidence
of bradycardia at time of release of tourniquet, and sedation
during the next 30 min.
Some studies have shown that tramadol has a local anes-
thetic action but the exact mechanism is still unknown [18].
Tramadol is related to codeine in its structure [19] and is selec-
tive for the mu-receptors [7] but the action on opioid receptors
does not explain its local effect [20]. Moreover, fentanyl when
added to local anesthetic for IVRA [21] did not has an adju-
vant effect supporting the hypothesis of absent peripheral opi-
oid-mediated mechanism during IVRA.
In a study by Acalovschi and coworkers [16] 100 mg tram-
adol enhanced the local anesthetic effect when added to 0.5%
lidocaine for IVRA. This was in accordance with the results
obtained in the present study. In their study, there were no
effect for tramadol on motor block and they explained that
by the small concentration of tramadol solution. However,
the results obtained by Kapral and coworkers [20] showed
prolonged motor block of the brachial plexus when same con-
centration of tramadol was added to mepivacaine for axillary
brachial plexus block. The results of the current study came
in accordance with the results obtained by Kapral and his col-
leagues regarding the effect of tramadol on motor block [20].
a2-Adrenergic receptors that are present at nerve endings
plays a role in pain modulation and some drugs perform their
analgesic functions by preventing norepinephrine release at
these receptors [22].Tramadol can block the reuptake of the norepinephrine
and 5-hydroxy-tryptamine at the a2*adrenergic receptors
[23]. Thereby, tramadol has an action similar to that of cloni-
dine a2-agonists, which inhibits the release of norepinephrine
from a2-adrenoceptors agonists [24].
Clonidine depresses nerve action potential by a mechanism
other than its effect on a2-adrenergic receptors which may ac-
count for perineural adjuvant effect to local anesthetics [25].
Adding clonidine to local anesthetics during IVRA revealed
controversial results. Kleinschmidt and coworkers [26] found
that clonidine did not add to the pattern of postoperative anal-
gesia, while, Reuben and coworkers [27] found that clonidine
made postoperative analgesia better. DEX is more selective
to a2-adrenoceptors than clonidine [15]. Thus, we thought that
addition of DEX to lidocaine will not be associated with such
debate. However, the patient safety was our target. Jaakola
[28] was also interested in both efﬁcacy and safety of IV dex-
medetomidine and he used it as a premedication before IVRA.
The results of that study revealed that 1 l/kg dexmedetomidine
produced desirable sedation, attenuated sympathoadrenal re-
sponses, and decreased opioid analgesic requirements but it
did not prevent tourniquet pain.
Tourniquet pain is a major problem that comes after the use
of a pneumatic tourniquet during surgical procedures involving
the upper or lower limb. The mechanism by which tourniquet
pain is elicited is yet unclear [29]. Many studies [4,30,31], have
shown that using clonidine during IVRA decreased tourniquet
pain. Clonidine has approximately 1/8 the potency Dexmede-
tomidine [14]. In the study by Memis and his colleagues [32],
tourniquet pain was attenuated and total fentanyl consumption
was reduced by adding dexmedetomidine to lidocaine solution
Lidocaine-tramadol versus lidocaine-dexmedetomidine for intravenous regional anesthesia 41during IVRA. This was in accordance with the results obtained
in the present study.
A major concern while using either tramadol or DEX as
adjuvants to local anesthetics is the possibility of subsequent
complications. In the current study, 30% of the patients in
tramadol group experienced skin rash distal to the tourniquet,
implying histamine release. This complication was also
encountered in the study by Acalovschi and his colleagues [16].
Abrupt IV introduction of 0.5–2 lg/kg dexmedetomidine
results in moderate hypotension, bradycardia, and sedation
[33]. In his study, Memis and his colleagues [32] found that
the addition of 0.5 lg/kg dexmedetomidine to lidocaine for
IVRA enhanced the anesthetic and postoperative analgesic
effect of lidocaine with cardiovascular stability during intra-
and postoperative times. In the current study, bradycardia
was detected in 35% of patients after release of tourniquet
which might be explained by the higher dose of dexmedetom-
idine (1 lg/kg). The bradycardia observed in Group D was
accompanied by insigniﬁcant decrease in blood pressure and
might be attributed to sympathetic inhibition and decreased
levels of circulating catecholamines caused by dexmedetomi-
dine [14].
In the study by Memis and his colleagues [32], no sedation
was detected with the use of 0.5 lg/kg dexmedetomidine for
IVRA during intra-operative or postoperative period. This
was not in agreement with the results obtained in the current
study where Ramsay sedation score was signiﬁcantly higher
after tourniquet deﬂation in dexmedetomidine group and
lasted for 30 min after which mat be attributed to the higher
dose of dexmedetomidine used (1 lg/kg). Our results agreed
with the results obtained by another study [34] which showed
that even small doses of a2-adrenergic agonists produce
sedation.5. Recommendations
According to the results obtained in the current study, either
tramadol or dexmedetomidine can be used as an adjuvant to
lidocaine during IVRA taking into considerations the possibil-
ity of relevant complications.6. Conclusion
Either 100 mg tramadol or 1 lg/kg dexmedetomidine equipo-
tently improves the performance of lidocaine when used during
IVRA with higher incidence of localized skin rash with trama-
dol and higher incidence of postoperative bradycardia and
sedation with dexmedetomidine.References
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